MAPT and early-onset autosomal dominant Alzheimer disease: Bosutinib treatment also enhanced the clearance of neurotoxic proteins α-amyloid and tau, leading to cognitive improvement in Alzheimer’s disease mouse models (Lonskaya et al., 2013a; Lonskaya et al., 2013b; Hebron et al., 2018).